FDA forces Concert Pharma to hit the brakes on a mid-stage study so it can review tox studies

FDA forces Concert Pharma to hit the brakes on a mid-stage study so it can review tox studies

Submitted by admin on May 17, 2017 - 9:34am
Source: 
Endpoints
News Tags: 
FDA
Concert Pharmaceuticals
clinical trials
CTP-543
alopecia areata
Headline: 
FDA forces Concert Pharma to hit the brakes on a mid-stage study so it can review tox studies

Do Not Allow Advertisers to Use My Personal information